Regional And Global Antimicrobial Susceptibilit...

Chemotherapeutic Potential Of 17-aag Against Cu...

Determination Of Vancomycin Minimum Inhibitory ...

Crovirin, A Snake Venom Cysteine-rich Secretory...

Assessment Of Anthelmintic Efficacy Of Mebendaz...

0 votes
Determination Of Vancomycin Minimum Inhibitory Concentration For Ceftazidime Resistant Streptococcus Pneumoniae In Iran
Author: Ramezan Ali Ataee,samira Habibian, Ali Mehrabi-tavana ,zyanab Ahmadi,nematollah Jonaidi,mahmood Salesi
Publisher: Derivative Works
18 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Article
ISBN/ISSN: 1476-0711
DOI: 10.1186/s12941-014-0053-1
Follow this publisher

Share this publication:


Background: In the context of growing health concerns over antibiotic resistance, the evaluation of the minimum inhibitory concentration (MIC) of vancomycin for Streptococcus pneumoniae (S. pneumoniae) strains resistant to ceftazidime becomes important for guiding health policy makers. The aim of this study was to determine vancomycin MIC of ceftazidime resistant S. pneumoniae strains.

Methods: Fifty identified serotypes of ceftazidime resistant S. pneumoniae strains were included in the study. The vancomycin MIC of the above mentioned bacteria was determined based on the 0.5 McFarland standards, by using a microdilution broth and the Etest method.

Results: The results showed that out of 50 ceftazidime resistant strains of S. pneumoniae, 46 strains (92%) have shown a vancomycin MIC ?0.19???0.1.5??g/ml and only four strains (8%) have shown a vancomycin MIC equal to 1.5??g/ml and the related maximum zone of inhibition was of 10 millimeter diameters.

Conclusions: The results of this investigation point out the emergence of S. pneumoniae strains with a vancomycin MIC ?1.5??g/ml, which were resistant to ceftazidime. This finding uncovers a major health concern: a vancomycin MIC higher than 1.5??g/ml and maximum zone of inhibition of only 10 millimeter. These findings represent an important warning for health authorities globally, concerning the treatment of patients, as the occurrence of S. pneumoniae strains with decreased vancomycin susceptibility has been demonstrated.

About the publisher:

We are a publishing house devoted to reuse CC-BY licensed published materials.


Using CC-BY licenses:


  • Adapt — remix, transform, and build upon the material
  • for any purpose, even commercially.
  • The licensor cannot revoke these freedoms as long as you follow the license terms.


  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others
    from doing anything the license permits.


  • You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
  • No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

Select a payment method